Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Almost every corner of modern medicine and sustainable food production today is facing a massive challenge: how do we outpace drug-resistant “superbugs” and create food for a growing population using fewer resources?

Bioprocessing

You might believe that bioprocess development is simple, perhaps even lacking in innovation, a perception shared by many scientists in basic research. However, this view is misguided.

Bioprocessing

What hidden engine drives biopharma’s relentless pursuit of faster, more reliable, and cost-effective therapies?

Bioprocessing

The biopharmaceutical industry is poised for a digital transformation.

Bioprocessing

Continuous manufacturing is no longer a futuristic concept. It’s here, and it’s rewriting the rules of biologics production.

Bioprocessing

Andrea Gough’s professional path began in medical microbiology, screening hospital samples for methicillin-resistant Staphylococcus aureus.

Data & Analytics

For years, protein engineering has struggled with a fundamental bottleneck: machine learning models, powerful as they are, have been starved of meaningful data.

Data & Analytics

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process.

Data & Analytics

AI won’t replace your bioprocessing team—but it will make them more indispensable than ever.

Data & Analytics

What if the secret to reliable, real-time bioprocessing isn’t buried in another wet-lab experiment, but hiding inside your data—waiting for the right digital ally?

Data & Analytics

If you could run an experiment in your computer instead of the lab—and it actually gave you answers worth acting on—would you try it?

Data & Analytics

Imagine trimming years off biologics development—and catching problematic formulations long before the first pipette is even picked up.

Biotech Success

Ever watched judges’ faces light up during your pitch?

Biotech Success

Ever stood in front of a room full of executives, your heart pounding, wondering why your brilliant science isn’t connecting?

Biotech Success

What happens when therapeutic innovation meets real patient urgency?

Biotech Success

Real urgency in healthcare means balancing safety, impact, and accessibility—not just speeding to market.

Biotech Success

What’s the single most formidable hurdle for a promising biotech breakthrough? It’s crafting a robust CMC (Chemistry, Manufacturing, and Controls) strategy.

Biotech Success

Bioprocess development and manufacturing are often perceived as sources of potential high-stakes problems, frequently cited as contributing to program failures.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Innovation

What if the breakthrough in AI-driven protein therapeutics hinges less on machine learning algorithms and more on a bold rethink of how companies share their most valuable resource—data?

Innovation

There’s a reason so many “picture-perfect” protein designs never make it past the computer screen: the leap from simulation to real-world function is wider than it looks.

Innovation

Is a future without heart attacks and strokes within reach—not just delayed, but truly reversed?

Innovation

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.